Our Take
The discovery is real and publishable (Nature), but the clinical leap from mice to humans rests on repurposing a drug shelved for other reasons—early-stage preclinical work, not a ready-to-deploy therapeutic.
Why it matters
Statins and PCSK9 inhibitors don't work for all patients, and understanding why diet sabotages the liver's own cholesterol-removal machinery opens a genuinely separate mechanism from existing drugs. The fact that a CTSA inhibitor already exists and passed Phase I safety testing means the path to human testing is plausible, not speculative.
Do this week
Cardiology and lipid researchers: monitor ClinicalTrials.gov for the Phase II announcement of SAR164653 for hypercholesterolemia by Q3 2025 so you can refer appropriate treatment-resistant patients.
UC San Diego team maps a cholesterol-clearing bottleneck
Researchers at UC San Diego School of Medicine identified a protein pathway, centered on a protein called Ral, that degrades LDL receptors on liver cells in response to dietary cholesterol. The finding appears in Nature, in a paper titled "Dietary cholesterol activates a Ral-dependent pathway driving LDLR turnover."
LDL receptors are the liver's docking stations for clearing harmful cholesterol from the blood. The more receptors remain on the cell surface, the more LDL gets removed. The team found that high dietary cholesterol activates Ral, which engages a complex that routes receptors to lysosomes, where an enzyme called cathepsin A (CTSA) degrades them. Blocking CTSA with a small molecule inhibitor called SAR164653 stabilized LDL receptors and lowered circulating LDL cholesterol in mice.
The drug candidate has already been tested in humans. SAR164653 advanced to Phase I clinical trial for heart failure, where it showed safety, before being shelved for strategic reasons unrelated to toxicity. The researchers propose testing it in Phase II for high cholesterol.
A new lever independent of existing cholesterol drugs
Current therapies (statins, PCSK9 inhibitors) preserve or increase LDL receptors by other mechanisms. This Ral pathway is separate. That matters because many patients cannot achieve safe cholesterol levels or cannot tolerate side effects of approved drugs. According to the paper, the mechanism is activated specifically by dietary cholesterol, revealing what the researchers call "a previously unrecognized molecular switch."
The shortcut: a drug already deemed safe in humans, rather than one requiring full preclinical safety validation. Senior author Alan Saltiel, director of the UC San Diego/UCLA Diabetes Research Center, said: "There's an experimental drug sitting on the shelf that's already been shown to be safe in humans." That eliminates a major bottleneck in drug development, though it does not guarantee efficacy in high-cholesterol patients.
What to watch before committing to trials
The mouse studies are solid, but translation is uncertain. CTSA is a lysosomal protease with functions beyond LDL receptor turnover. Off-target effects in humans (liver, kidney, immune cells) cannot be ruled out based on Phase I heart-failure data alone. Phase II will run in cholesterol patients, not heart-failure patients, and the dosing, tolerability, and target-tissue selectivity may differ.
The pathway itself is a genuine addition to the cholesterol-biology toolkit and answers a decades-old question about why diet undermines the liver's clearance capacity. But moving from mouse confirmation to clinical utility in a disease with multiple existing options requires the trial to show both safety in the new population and meaningful LDL reduction—neither guaranteed by preclinical work or a prior Phase I in a different indication.